G protein-coupled receptor class C group 5 member BGenealiases: MLC3 · RAIG-2 · RAIG2
Q-omics provides the consensus-scored GPRC5B profile across patient tissues and cancer cell-line models. GPRC5B expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GPRC5B is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, GPRC5B RNA expression shows 18,828 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where GPRC5B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPRC5B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPRC5B survival associations across molecular data types. GPRC5B RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPRC5B RNA expression–survival associations across cancer types. High GPRC5B expression shows unfavorable associations in BLCA, COAD and KIRP, but favorable associations in KIRC, SKCM and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GPRC5B RNA expression.
This table summarizes GPRC5B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for GPRC5B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPRC5B shows lower tumor expression in KIRC, KIRP, BRCA and UCEC and higher tumor expression in THCA and LIHC. The KIRC box plot shows higher GPRC5B RNA expression in normal versus tumor tissue (log2 FC = −1.355, t-test p < 0.001).
This table shows molecular features associated with GPRC5B in patient tissues and cancer cell lines. In patient samples, GPRC5B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, GPRC5B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OVARY and SKIN.
